Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of namodenoson versus placebo in advanced hepatocellular carcinoma with Child-Pugh B7 cirrhosis
2021-005286-41Phase 3Active
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Namodenoson with Placebo (2 arms). Primary endpoint: Overall survival. Started Jul 2022; status: active.
02
Drugs
namodenoson
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2021-005286-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005286-41.